A quantitative analysis of the effect of glucose-insulin-potassium in acute myocardial infarction

Area of Science:

• Cardiology
• Clinical Trials
• Pharmacology

Background:

• ST-segment elevation acute myocardial infarction (STEMI) is a critical condition requiring timely intervention.
• Glucose-insulin-potassium (GIK) therapy has been explored as a potential treatment to improve outcomes in STEMI.
• The clinical benefit of varying GIK doses in STEMI remains a subject of investigation.

Purpose of the Study:

• To systematically review and analyze existing data on the efficacy of high- and low-dose glucose-insulin-potassium (GIK) therapy.
• To determine the clinical benefit of GIK in patients diagnosed with ST-segment elevation acute myocardial infarction (STEMI).

Main Methods:

• A meta-analysis was conducted on data from 16 randomized controlled trials.
• Searches included electronic and manual methods to identify relevant GIK trials in STEMI patients.
• The primary endpoint for the meta-analysis was 30-day mortality.

Main Results:

• The analysis included 26,273 patients from studies conducted between 1962 and 2005.
• Overall hospital mortality was 9.6% in the GIK group versus 10.2% in control groups (p=0.088).
• Glucose-insulin-potassium infusion was not associated with an increased risk of major adverse events.

Conclusions:

• This meta-analysis found no significant beneficial or detrimental effect of GIK infusion on 30-day mortality in STEMI patients.
• The findings suggest that GIK infusion should not be considered a standard treatment for STEMI.
• Further research may be needed to fully elucidate any potential role of GIK in specific cardiovascular contexts.